Australian trial defines ideal prostate therapy
The finding means many men will be spared the long-term side effects linked to testosterone-suppression therapy
Australian researchers believe they’ve hit on the optimum duration of hormone-suppression therapy for men with aggressive, localised prostate cancers after a 10-year trial.
The findings from the RADAR study — which followed more than 1000 Australian men with advanced prostate cancer — show that 18 months of androgen suppression, coupled with moderate radiation dose escalation, is both tolerable and effective.
